Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: Requirement for comprehensive complement analysis

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 9, 2014, Pages 1437-1439

  Wehling, C ^a   Kirschfink, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; ECULIZUMAB; MONOCLONAL ANTIBODY;

COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; DISEASE COURSE; DRUG ACCUMULATION; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENETIC ANALYSIS; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; MAINTENANCE THERAPY; NOTE; REMISSION; ANTAGONISTS AND INHIBITORS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; FEMALE; MALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT C3; COMPLEMENT C5; FEMALE; HUMANS; MALE;

EID: 84908501417     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12639     Document Type: Note

References (19)

1. Kerr H, Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology 2012; 217: 195-203.
2. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622-33.
3. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, European Working Party on Complement Genetics in Renal D. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013; 24:475-86.
4. Ruebner RL, Kaplan BS, Copelovitch L. A time for reappraisal of 'atypical' hemolytic uremic syndrome: should all patients be treated the same? Eur J Pediatr 2012; 171: 1519-25.
5. Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transpl Proc 2012; 44: 3037-40.
6. Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 2014; pii:S0272-6386(14)00528-9. doi: 10.1053/j.ajkd.2014.01.434. [Epub ahead of print]
7. Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014; 12: 1440-8.
8. Mollnes TE, Jokiranta TS, Truedsson L, Nilsson B, Rodriguez de Cordba S, Kirschfink M. Complement analysis in the 21st century. Mol Immunol 2007; 44: 3838-49.
9. Tudoran R, Kirschfink M. Modern complement analysis: indications, methods and outlook. J Lab Med 2012; 36: 1-9.
10. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1312-16.
11. Wehling C, Amon O, Hohenstein B, Pape L, Bommer M, Kirschfink M. Eculizumab drug monitoring in serum and urine opens new insights into therapy of complement-mediated nephropathies. Mol Immunol 2013; 56: 257.
12. Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP. Blood 2014; 123: 3733-8.
13. Carr R, Cataland SR. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. Ann Hematol 2013; 92: 845-6.
14. Christmann M, Hansen M, Bergmann C, Schwabe D, Brand J, Schneider W. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome. Pediatrics 2014; 133: e1759-63.
15. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V, French Study Group for a HCG. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643-57.
16. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic- uremic syndrome. N Engl J Med 2013; 368: 2169-81.
17. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-13.
18. Barnett AN, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N. The use of eculizumab in renal transplantation. Clin Transplant 2013; 27: E216-29.
19. Burbach M, Suberbielle C, Brocheriou I, Ridel C, Mesnard L, Dahan K, Rondeau E, Hertig A. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 2014; [Epub ahead of print]